Cutaneous B-cell lymphomas: 2015 update on diagnosis, risk-stratification, and management

American Journal of Hematology

Volumn 90, Issue 1, 2015, Pages 73-76

  Wilcox, Ryan A ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; INTERFERON REGULATORY FACTOR 4; PROTEIN BCL 2; PROTEIN BCL 6;

ARTICLE; B CELL LYMPHOMA; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CENTROBLAST; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; GENE EXPRESSION; GERMINAL CENTER; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOBLAST; IMMUNOHISTOCHEMISTRY; INTERNATIONAL PROGNOSTIC INDEX; LOWER LEG; LYMPHOID CELL; LYMPHOMA CELL; OVERALL SURVIVAL; PRIMARY CUTANEOUS DIFFUSE LARGE B CELL LYMPHOMA LEG TYPE; PRIMARY CUTANEOUS FOLLICLE CENTER LYMPHOMA; PRIMARY CUTANEOUS MARGINAL ZONE LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PUNCH BIOPSY; RISK ASSESSMENT; SKIN BIOPSY; SKIN LYMPHOMA; LYMPHOMA, B-CELL, MARGINAL ZONE; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MORTALITY; PRACTICE GUIDELINE; PROGNOSIS; RADIOTHERAPY; RISK; SKIN NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RADIOTHERAPY; RISK; SKIN NEOPLASMS;

EID: 84919624533     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23863     Document Type: Article

References (28)

1. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768-3785.
2. Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009;113:5064-5073.
3. Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007;110:479-484.
4. Gellrich S, Rutz S, Golembowski S, et al. Primary cutaneous follicle center cell lymphomas and large B cell lymphomas of the leg descend from germinal center cells. A single cell polymerase chain reaction analysis. J Invest Dermatol 2001;117:1512-1520.
5. Hoefnagel JJ, Dijkman R, Basso K, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood 2005;105:3671-3678.
6. Cerroni L, Kerl H. Immunoreactivity for bcl-2 protein in cutaneous lymphomas and lymphoid hyperplasias. J Cutan Pathol 1995;22:476-478.
7. Cerroni L, Volkenandt M, Rieger E, et al. bcl-2 protein expression and correlation with the interchromosomal 14;18 translocation in cutaneous lymphomas and pseudolymphomas. J Invest Dermatol 1994;102:231-235.
8. Cerroni L, Arzberger E, Putz B, et al. Primary cutaneous follicle center cell lymphoma with follicular growth pattern. Blood 2000;95:3922-3928.
9. Grange F, Beylot-Barry M, Courville P, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol 2007;143:1144-1150.
10. Senff NJ, Hoefnagel JJ, Jansen PM, et al. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol 2007;25:1581-1587.
11. Mao X, Lillington D, Child F, et al. Comparative genomic hybridization analysis of primary cutaneous B-cell lymphomas: identification of common genomic alterations in disease pathogenesis. Genes Chromosomes Cancer 2002;35:144-155.
12. Koens L, Zoutman WH, Ngarmlertsirichai P, et al. Nuclear factor-kappaB pathway-activating gene aberrancies in primary cutaneous large B-cell lymphoma, leg type. J Invest Dermatol 2014;134:290-292.
13. Pham-Ledard A, Beylot-Barry M, Barbe C, et al. High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type. JAMA Dermatol 2014. [Epub ahead of print]
14. Cerroni L, Zochling N, Putz B, Kerl H. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol 1997;24:457-461.
15. Goodlad JR, Davidson MM, Hollowood K, et al. Borrelia burgdorferi-associated cutaneous marginal zone lymphoma: a clinicopathological study of two cases illustrating the temporal progression of B. burgdorferi-associated B-cell proliferation in the skin. Histopathology 2000;37:501-508.
16. Goodlad JR, Davidson MM, Hollowood K, et al. Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotland. Am J Surg Pathol 2000;24:1279-1285.
17. Wood GS, Kamath NV, Guitart J, et al. Absence of Borrelia burgdorferi DNA in cutaneous B-cell lymphomas from the United States. J Cutan Pathol 2001;28:502-507.
18. Senff NJ, Kluin-Nelemans HC, Willemze R. Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphoma. Br J Haematol 2008;142:52-56.
19. Smith BD, Smith GL, Cooper DL, Wilson LD. The cutaneous B-cell lymphoma prognostic index: a novel prognostic index derived from a population-based registry. J Clin Oncol 2005;23:3390-3395.
20. Zinzani PL, Quaglino P, Pimpinelli N, et al. Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. J Clin Oncol 2006;24:1376-1382.
21. Hamilton SN, Wai ES, Tan K, et al. Treatment and outcomes in patients with primary cutaneous B-cell lymphoma: the BC Cancer Agency experience. Int J Radiat Oncol Biol Phys 2013;87:719-725.
22. Grange F, Petrella T, Beylot-Barry M, et al. Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas. Blood 2004;103:3662-3668.
23. Hallermann C, Kaune KM, Gesk S, et al. Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas. J Invest Dermatol 2004;123:213-219.
24. Grange F, Bekkenk MW, Wechsler J, et al. Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol 2001;19:3602-3610.
25. Senff NJ, Noordijk EM, Kim YH, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 2008;112:1600-1609.
26. Bekkenk MW, Vermeer MH, Geerts ML, et al. Treatment of multifocal primary cutaneous B-cell lymphoma: a clinical follow-up study of 29 patients. J Clin Oncol 1999;17:2471-2478.
27. Dreno B. Standard and new treatments in cutaneous B-cell lymphomas. J Cutan Pathol 2006;33(Suppl 1):47-51.
28. Savini P, Lanzi A, Foschi FG, et al. Lenalidomide monotherapy in relapsed primary cutaneous diffuse large B cell lymphoma-leg type. Ann Hematol 2014;93:333-334.